Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Instagram Outage Disrupts Thousands of U.S. Users 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Samsung Bioepis Co. Ltd.'s commercial partner Organon will supply its Hadlima autoimmune disease treatment to the United States after winning an order from the U.S. Department of Veterans Affairs. It was agreed that U.S.-based Organon would deliver the biosimilar Hadlima drugs for five years.
Organon will now deliver Hadlima biosimilar treatment to the Department of Veterans Affairs (V.A.). This well-known drug is mainly used for medicating rheumatoid arthritis, spondyloarthritis, and psoriasis. According to The Korea Economic Daily, AbbVie Inc., a pharmaceutical company headquartered in North Chicago, Illinois, developed the original drug.
Orders from the U.S.
The latest order was revealed by Organon, the partner company of Samsung Bioepis based in the U.S. On Wednesday, Feb. 21, the firm said that Organon won a bidding contract to supply Hadlima to the American government agency. Consequently, Organon will supply Hadlima to hospitals under the Ministry of Veterans Affairs for the next five years.
The Veterans Affairs
The VA is a government agency for veterans in the United States. It provides benefits in various fields, such as medical care and finance, and is building a general hospital-level hospital network and medical infrastructure throughout the United States.
"America's veterans deserve access to quality medicines at a lower cost. We are proud to support the more than nine million people enrolled in the VA healthcare system through this collaboration, which is a great example of industry and public sector working together," Kevin Ali, Organon CEO, said in a press release. "We applaud the VA for its leadership in championing biosimilars and including all three of Organon's biosimilars available in the US on its formulary."
Photo by: Organon Media
